PET/CT在分化型甲状腺癌诊疗中的应用
Application of PET/CT in the Diagnosis and Treatment of Differentiated Thyroid Carcinoma
摘要: 近年来甲状腺癌发病率在全球呈快速增长态势，尤其是分化型甲状腺癌(differentiated thyroid carcinoma, DTC)。目前对DTC的诊疗，提倡精准化、个体化及根据患者动态评估结果实时调整治疗及随访管理的策略。正电子发射计算机断层扫描仪(Positron Emission Tomography/Computed Tomography, PET/CT)将核医学功能分子影像与计算机断层扫描(Computed Tomography, CT)的精细解剖影像完美结合，在肿瘤的临床特异性诊断及个体化精准治疗中发挥重要作用。但关于PET/CT在DTC诊疗中的应用价值，一直存在较多争议，本文结合国内外相关研究及进展对PET/CT在DTC中的应用情况进行综述。
Abstract: In recent years, the incidence of thyroid cancer has increased rapidly worldwide, particularly that of differentiated thyroid carcinoma (DTC). Current management of DTC emphasizes precision, individualization, and dynamic adjustment of treatment and follow-up strategies based on ongoing risk stratification and clinical evaluation. Positron emission tomography/computed tomography (PET/CT), which combines functional molecular imaging with anatomical imaging, has demonstrated important value in the diagnosis and treatment of malignant tumors. By integrating metabolic or molecular information with precise anatomical localization, PET/CT provides useful imaging support for individualized clinical decision-making. However, the value of PET/CT in the diagnosis and management of DTC remains controversial. Based on relevant domestic and international studies, this review summarizes the current applications of PET/CT in DTC and discusses recent research advances, with the aim of providing a reference for its further clinical application in the management of DTC.
文章引用：王蕊, 段东. PET/CT在分化型甲状腺癌诊疗中的应用[J]. 临床医学进展, 2026, 16(4): 1453-1460. https://doi.org/10.12677/acm.2026.1641379

参考文献

[1] Han, B., Zheng, R., Zeng, H., Wang, S., Sun, K., Chen, R., et al. (2024) Cancer Incidence and Mortality in China, 2022. Journal of the National Cancer Center, 4, 47-53. [Google Scholar] [CrossRef] [PubMed]
[2] 甲状腺细针穿刺细胞病理学诊断专家共识编写组, 中华医学会病理学分会细胞病理学组. 甲状腺细针穿刺细胞病理学诊断专家共识(2023版) [J]. 中华病理学杂志, 2023, 52(5): 441-446.
[3] Li, Y., Wang, Q., Wang, X., Li, X., Wu, H., Wang, Q., et al. (2020) Expert Consensus on Clinical Application of FDG PET/CT in Infection and Inflammation. Annals of Nuclear Medicine, 34, 369-376. [Google Scholar] [CrossRef] [PubMed]
[4] 刘桂超, 高硕, 蔡莉, 等. 肺外结核39例临床表现与18F-氟脱氧葡萄糖正电子发射计算机断层成像-CT的特点分析[J]. 中华结核和呼吸杂志, 2012, 35(3): 184-188.
[5] Soelberg, K.K., Bonnema, S.J., Brix, T.H. and Hegedüs, L. (2012) Risk of Malignancy in Thyroid Incidentalomas Detected by 18F-Fluorodeoxyglucose Positron Emission Tomography: A Systematic Review. Thyroid, 22, 918-925. [Google Scholar] [CrossRef] [PubMed]
[6] 吉婷, 杨爱民. 18F-FDG PET/CT显像对甲状腺偶发结节的诊断价值[J]. 标记免析与临床, 2023, 30(11): 1846-1852.
[7] 彭民, 石华铮, 熊爱民, 等. 超声联合18F-FDG PET/CT对甲状腺乳头状癌术后复发转移的诊断价值[J]. 肿瘤影像学, 2020, 29(4): 365-369.
[8] Bae, M.R., Roh, J., Kim, J.S., Lee, J.H., Cho, K., Choi, S., et al. (2019) 18F-FDG PET/CT versus CT/MR Imaging for Detection of Neck Lymph Node Metastasis in Palpably Node-Negative Oral Cavity Cancer. Journal of Cancer Research and Clinical Oncology, 146, 237-244. [Google Scholar] [CrossRef] [PubMed]
[9] Maruoka, Y., Baba, S., Isoda, T., Kitamura, Y., Abe, K., Sasaki, M., et al. (2017) Association between Volumetric Analysis of Lung Metastases on F-18-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography and Short-Term Progression after I-131 Therapy for Differentiated Thyroid Carcinoma. Indian Journal of Nuclear Medicine, 32, 167-172. [Google Scholar] [CrossRef] [PubMed]
[10] Treglia, G., Annunziata, S., Muoio, B., Salvatori, M., Ceriani, L. and Giovanella, L. (2013) The Role of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Aggressive Histological Subtypes of Thyroid Cancer: An Overview. International Journal of Endocrinology, 2013, 1-6. [Google Scholar] [CrossRef] [PubMed]
[11] Zajkowska, K., Cegla, P. and Dedecjus, M. (2024) Role of [18F]FDG PET/CT in the Management of Follicular Cell-Derived Thyroid Carcinoma. Cancer Imaging, 24, Article No. 147. [Google Scholar] [CrossRef] [PubMed]
[12] Ozkan, E., Soydal, C., Kucuk, O.N., Ibis, E. and Erbay, G. (2011) Impact of 18F-FDG PET/CT for Detecting Recurrence of Medullary Thyroid Carcinoma. Nuclear Medicine Communications, 32, 1162-1168. [Google Scholar] [CrossRef] [PubMed]
[13] Vogel, J., Sekler, J., Gückel, B., Pfannenberg, C., Nikolaou, K., La Fougère, C., et al. (2024) How [18F]FDG-PET/CT Affects the Management of Patients with Differentiated Thyroid Carcinoma in Clinical Routines. Cancers, 16, Article No. 588. [Google Scholar] [CrossRef] [PubMed]
[14] Rendl, G., Rettenbacher, L., Schweighofer-Zwink, G., Hehenwarter, L. and Pirich, C. (2020) Pre-Ablation rhTSH-Stimulated F-18 FDG PET/CT Changes Patient Management in Increased-Risk Thyroid Cancer. Hormone and Metabolic Research, 52, 158-167. [Google Scholar] [CrossRef] [PubMed]
[15] Song, Y., Liu, F., Ruan, W., Hu, F., Younis, M.H., Gao, Z., et al. (2021) Head-to-Head Comparison of Neck 18F-FDG PET/MR and PET/CT in the Diagnosis of Differentiated Thyroid Carcinoma Patients after Comprehensive Treatment. Cancers, 13, Article No. 3436. [Google Scholar] [CrossRef] [PubMed]
[16] Lee, J.W., Lee, S.M., Lee, D.H. and Kim, Y.J. (2013) Clinical Utility of 18F-FDG PET/CT Concurrent with 131I Therapy in Intermediate-to-High-Risk Patients with Differentiated Thyroid Cancer: Dual-Center Experience with 286 Patients. Journal of Nuclear Medicine, 54, 1230-1236. [Google Scholar] [CrossRef] [PubMed]
[17] Liu, M., Cheng, L., Jin, Y., Ruan, M., Sheng, S. and Chen, L. (2018) Predicting 131I-Avidity of Metastases from Differentiated Thyroid Cancer Using 18F-FDG PET/CT in Postoperative Patients with Elevated Thyroglobulin. Scientific Reports, 8, Article No. 4352. [Google Scholar] [CrossRef] [PubMed]
[18] Haugen, B.R., Alexander, E.K., Bible, K.C., Doherty, G.M., Mandel, S.J., Nikiforov, Y.E., et al. (2016) 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 26, 1-133. [Google Scholar] [CrossRef] [PubMed]
[19] Bang, J.I., Park, S., Kim, K., Seo, Y., Chong, A., Hong, C.M., et al. (2023) The Diagnostic Value of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Differentiated Thyroid Cancer Patients with Elevated Thyroglobulin/Thyroglobulin Antibody Levels and Negative Iodine Scintigraphy: A Systematic Review and Meta-Analysis. Thyroid, 33, 1224-1236. [Google Scholar] [CrossRef] [PubMed]
[20] Albano, D., Tulchinsky, M., Dondi, F., Mazzoletti, A., Lombardi, D., Bertagna, F., et al. (2021) Thyroglobulin Doubling Time Offers a Better Threshold than Thyroglobulin Level for Selecting Optimal Candidates to Undergo Localizing [18F]FDG PET/CT in Non-Iodine Avid Differentiated Thyroid Carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 48, 461-468. [Google Scholar] [CrossRef] [PubMed]
[21] Matsuo, M., Baba, S., Hashimoto, K., Isoda, T., Kitamura, Y., Kogo, R., et al. (2023) Utility of FDG PET at the Initial Radioiodine Therapy in Differentiated Thyroid Cancer. Anticancer Research, 43, 183-190. [Google Scholar] [CrossRef] [PubMed]
[22] 唐潇伟, 施良, 王俊, 赵震宇, 卜婷, 王峰. (18)F-FDG PET/CT鉴别高危及碘难治性分化型甲状腺癌的价值[J]. 中国医学影像学杂志, 2022, 30(3): 210-214+229.
[23] Lodi Rizzini, E., Repaci, A., Tabacchi, E., Zanoni, L., Vicennati, V., Cavicchi, O., et al. (2021) Impact of 18F-FDG PET/CT on Clinical Management of Suspected Radio-Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC). Diagnostics, 11, Article 1430. [Google Scholar] [CrossRef] [PubMed]
[24] Ahmaddy, F., Burgard, C., Beyer, L., Koehler, V.F., Bartenstein, P., Fabritius, M.P., et al. (2021) 18F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib. Cancers, 13, Article No. 317. [Google Scholar] [CrossRef] [PubMed]
[25] Roy, M., Edet-Sanson, A., Lefebvre, H., Vera, P. and Decazes, P. (2022) Using 18F-FDG-PET/CT Metrics to Predict Survival in Ra-Dio-Iodine Refractory Thyroid Cancers. Diagnostics, 12, Article 2381. [Google Scholar] [CrossRef] [PubMed]
[26] Wu, D., Ylli, D., Heimlich, S.L., Burman, K.D., Wartofsky, L. and Van Nostrand, D. (2019) 124 I Positron Emission Tomography/Computed Tomography versus Conventional Radioiodine Imaging in Differentiated Thyroid Cancer: A Review. Thyroid, 29, 1523-1535. [Google Scholar] [CrossRef] [PubMed]
[27] Wong, B.Z.Y., Dickie, G., Garcia, P., Scott, D. and Pattison, D.A. (2021) 124I-PET/CT-Guided Diagnosis and Personalized Treatment of Metastatic Papillary Thyroid Cancer to the Pancreas. Clinical Nuclear Medicine, 46, 337-339. [Google Scholar] [CrossRef] [PubMed]
[28] Dittmann, M., Gonzalez Carvalho, J.M., Rahbar, K., Schäfers, M., Claesener, M., Riemann, B., et al. (2020) Incremental Diagnostic Value of [18F]Tetrafluoroborate PET-CT Compared to [131I]Iodine Scintigraphy in Recurrent Differentiated Thyroid Cancer. European Journal of Nuclear Medicine and Molecular Imaging, 47, 2639-2646. [Google Scholar] [CrossRef] [PubMed]
[29] Ventura, D., Dittmann, M., Büther, F., Schäfers, M., Rahbar, K., Hescheler, D., et al. (2024) Diagnostic Performance of [18F]TFB PET/CT Compared with Therapeutic Activity [131I]Iodine SPECT/CT and [18F]FDG PET/CT in Recurrent Differentiated Thyroid Carcinoma. Journal of Nuclear Medicine, 65, 192-198. [Google Scholar] [CrossRef] [PubMed]
[30] Verma, P., Malhotra, G., Meshram, V., Chandak, A., Sonavane, S., Lila, A.R., et al. (2021) Prostate-Specific Membrane Antigen Expression in Patients with Differentiated Thyroid Cancer with Thyroglobulin Elevation and Negative Iodine Scintigraphy Using 68Ga-PSMA-HBED-CC PET/CT. Clinical Nuclear Medicine, 46, e406-e409. [Google Scholar] [CrossRef] [PubMed]
[31] Lütje, S., Gomez, B., Cohnen, J., Umutlu, L., Gotthardt, M., Poeppel, T.D., et al. (2017) Imaging of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT. Clinical Nuclear Medicine, 42, 20-25. [Google Scholar] [CrossRef] [PubMed]
[32] de Vries, L.H., Lodewijk, L., Braat, A.J.A.T., Krijger, G.C., Valk, G.D., Lam, M.G.E.H., et al. (2020) 68Ga-PSMA PET/CT in Radioactive Iodine-Refractory Differentiated Thyroid Cancer and First Treatment Results with 177Lu-PSMA-617. EJNMMI Research, 10, Article No. 18. [Google Scholar] [CrossRef] [PubMed]
[33] Pazaitou-Panayiotou, K., Janson, E.T., Koletsa, T., Kotoula, V., Stridsberg, M., Karkavelas, G., et al. (2012) Somatostatin Receptor Expression in Non-Medullary Thyroid Carcinomas. Hormones, 11, 290-296. [Google Scholar] [CrossRef] [PubMed]
[34] Parihar, A.S., Mittal, B.R., Kumar, R., Shukla, J. and Bhattacharya, A. (2020) 68Ga-Dota-Rgd 2 Positron Emission Tomography/Computed Tomography in Radioiodine Refractory Thyroid Cancer: Prospective Comparison of Diagnostic Accuracy with 18F-FDG Positron Emission Tomography/Computed Tomography and Evaluation toward Potential Theranostics. Thyroid, 30, 557-567. [Google Scholar] [CrossRef] [PubMed]
[35] Fu, H., Fu, J., Huang, J., Pang, Y. and Chen, H. (2021) 68Ga-FAPI PET/CT versus 18F-FDG PET/CT for Detecting Metastatic Lesions in a Case of Radioiodine-Refractory Differentiated Thyroid Cancer. Clinical Nuclear Medicine, 46, 940-942. [Google Scholar] [CrossRef] [PubMed]
[36] Chen, H., Pang, Y., Wu, J., Zhao, L., Hao, B., Wu, J., et al. (2020) Comparison of [68Ga]Ga-Dota-FAPI-04 and [18F] FDG PET/CT for the Diagnosis of Primary and Metastatic Lesions in Patients with Various Types of Cancer. European Journal of Nuclear Medicine and Molecular Imaging, 47, 1820-1832. [Google Scholar] [CrossRef] [PubMed]
[37] Fu, H., Wu, J., Huang, J., Sun, L., Wu, H., Guo, W., et al. (2022) 68Ga Fibroblast Activation Protein Inhibitor PET/CT in the Detection of Metastatic Thyroid Cancer: Comparison with 18F-FDG PET/CT. Radiology, 304, 397-405. [Google Scholar] [CrossRef] [PubMed]
[38] Mu, X., Huang, X., Jiang, Z., Li, M., Jia, L., Lv, Z., et al. (2022) [18F]FAPI-42 PET/CT in Differentiated Thyroid Cancer: Diagnostic Performance, Uptake Values, and Comparison with 2-[18F]FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 50, 1205-1215. [Google Scholar] [CrossRef] [PubMed]

为你推荐